Posts by VIVA! Communications
A potential vaccine for cancer: new data
After nearly half a century of trying to identify a vaccine that might wipe out cancers, similarly to the way vaccine targets influenza or pneumococcal pneumonia, scientists might have made a breakthrough in this arena. According to an article published in The Australian (July 7, 2017), scientists from a German biotechnology company, Biontech, as well as…
Read MoreApotex launches Oviit a new range of vitamins and minerals
Apotex announced the launch of its new premium value, Pharmacy Only range of vitamin and mineral supplements (VMS), Oviit today (July 3, 2017). Expansion into this high growth VMS category signals further diversification of Apotex’s over-the-counter (OTC) portfolio, and a strategy for the generic drug manufacturer to restore value to the VMS category for pharmacy.…
Read MoreAussie biotech appoints American royalty to its Board of Directors
VIVA! Communications are thrilled to be working with Australian medical technology company Medibio as they today (June 4, 2017) announce the appointment of mental health advocate and former U.S. congressman, Patrick J. Kennedy, to their Board of Directors. Patrick J. Kennedy is a former member of the U.S. House of Representatives and America’s leading political…
Read MoreGovernment adds $142 million in medicines to PBS
As of July 1, 2017, the Federal Government has made AUD$142 million in new medicine listings to the Pharmaceutical Benefits Scheme (PBS), in a bid to make more medicines affordable to all Australians. Among the new listings, the PBS will fund access to vorinostat to treat patients living a subtype of blood cancer, non-Hodgkin’s lymphoma called…
Read MoreScientific breakthrough on objective diagnosis of PTSD
Findings from an Emory University, USA research study* released this week demonstrate a non-invasive protocol involving heart rate data and machine learning algorithms can accurately diagnose post-traumatic stress disorder (PTSD). The Classification of post-traumatic stress disorder from heart rate variability metrics with heart rate-based window segmentation study, involving technology developed by Emory University and licensed…
Read More